These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33963708)

  • 1. [Synergistic effect of polysaccharide from
    Li P; Yuan P; Que Y; Liu X; Wang G
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Apr; 41(4):504-513. PubMed ID: 33963708
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Ma L; Ai F; Xiao H; Wang F; Shi L; Bai X; Zhu Y; Ma W
    Front Pharmacol; 2024; 15():1367747. PubMed ID: 38576495
    [No Abstract]   [Full Text] [Related]  

  • 3. Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo.
    Yang S; Li W; Sun H; Wu B; Ji F; Sun T; Chang H; Shen P; Wang Y; Zhou D
    BMC Cancer; 2015 Dec; 15():969. PubMed ID: 26674205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway.
    Huang C; Zhou T; Ma L; Zhao S
    Biol Pharm Bull; 2023; 46(1):26-34. PubMed ID: 36596524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin F
    Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
    World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells.
    Wang M; Xiang Y; Wang R; Zhang L; Zhang H; Chen H; Luan X; Chen L
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36431875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells.
    Zhang Z; Shen C; Zhou F; Zhang Y
    Drug Dev Res; 2023 May; 84(3):542-555. PubMed ID: 36779379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
    Zhang J; Li C; Sun L; Sun D; Zhao T
    Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
    Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
    Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
    Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
    Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
    Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
    Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.
    Martin-Fernandez C; Bales J; Hodgkinson C; Welman A; Welham MJ; Dive C; Morrow CJ
    Mol Cancer Res; 2009 Jun; 7(6):955-65. PubMed ID: 19509113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell.
    Wang Z; Sun X; Feng Y; Wang Y; Zhang L; Wang Y; Fang Z; Azami NLB; Sun M; Li Q
    Phytomedicine; 2021 Feb; 82():153414. PubMed ID: 33461143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [ASPP2 inhibits oxaliplatin-induced autophagy and promotes apoptosis of colon cancer cells].
    Wang B; Qiao L; Shi Y; Feng X; Chen D; Guo H
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jul; 31(7):898-904. PubMed ID: 26146058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.
    Liu Y; Bi T; Wang Z; Wu G; Qian L; Gao Q; Shen G
    Apoptosis; 2016 Dec; 21(12):1398-1407. PubMed ID: 27671687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
    Gao R; Fang C; Xu J; Tan H; Li P; Ma L
    Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin-loaded nanoemulsion containing
    Al-Otaibi WA; AlMotwaa SM
    Drug Deliv; 2022 Dec; 29(1):2190-2205. PubMed ID: 35815706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
    Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
    Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer.
    Zhang Q; Zhou Y; Feng X; Gao Y; Huang C; Yao X
    Biomed Pharmacother; 2022 Sep; 153():113426. PubMed ID: 36017794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer.
    Wang K; Liu L; Zhang T; Zhu YL; Qiu F; Wu XG; Wang XL; Hu FQ; Huang J
    Int J Nanomedicine; 2011; 6():3207-18. PubMed ID: 22238509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.